Literature DB >> 17457318

Ras transformation mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity, and apoptosis-dependent release.

Paola Marcato1, Maya Shmulevitz, Da Pan, Don Stoltz, Patrick Wk Lee.   

Abstract

Reovirus, a potential cancer therapy, replicates more efficiently in Ras-transformed cells than in non-transformed cells. It was presumed that increased translation was the mechanistic basis of reovirus oncolysis. Analyses of each step of the reovirus life cycle now show that cellular processes deregulated by Ras transformation promote not one but three viral replication steps. First, in Ras-transformed cells, proteolytic disassembly (uncoating) of the incoming virions, required for onset of infection, occurs more efficiently. Consequently, threefold more Ras-transformed cells become productively infected with reovirus than non-transformed cells, which accounts for the observed increase of reovirus proteins in Ras-transformed cells. Second, Ras transformation increases the infectious-to-noninfectious virus particle ratio, as virions purified from Ras-transformed cells are fourfold more infectious than those purified from non-transformed cells. Progeny assembled in non- and Ras-transformed cells appear similar by electron microscopy and sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis, suggesting that Ras transformation introduces a subtle change necessary for virus infectivity. Finally, reovirus release, mediated by caspase-induced apoptosis, is ninefold more efficient in Ras-transformed cells. The combined effects of enhanced virus uncoating, infectivity, and release result in >100-fold differences in virus titers within one round of replication. Our analysis reveals previously unrecognized mechanisms by which Ras transformation mediates selective viral oncolysis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17457318     DOI: 10.1038/sj.mt.6300179

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  78 in total

1.  REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer.

Authors:  Charles Comins; James Spicer; Andrew Protheroe; Victoria Roulstone; Katie Twigger; Christine M White; Richard Vile; Alan Melcher; Matt C Coffey; Karl L Mettinger; Gerard Nuovo; David E Cohn; Mitch Phelps; Kevin J Harrington; Hardev S Pandha
Journal:  Clin Cancer Res       Date:  2010-10-06       Impact factor: 12.531

2.  Reovirus variants with mutations in genome segments S1 and L2 exhibit enhanced virion infectivity and superior oncolysis.

Authors:  Maya Shmulevitz; Shashi A Gujar; Dae-Gyun Ahn; Adil Mohamed; Patrick W K Lee
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

3.  Replicating reoviruses with a transgene replacing the codons for the head domain of the viral spike.

Authors:  D J M van den Wollenberg; I J C Dautzenberg; W Ros; A D Lipińska; S K van den Hengel; R C Hoeben
Journal:  Gene Ther       Date:  2015-01-15       Impact factor: 5.250

4.  Reduction of virion-associated σ1 fibers on oncolytic reovirus variants promotes adaptation toward tumorigenic cells.

Authors:  Adil Mohamed; Carmit Teicher; Sarah Haefliger; Maya Shmulevitz
Journal:  J Virol       Date:  2015-02-04       Impact factor: 5.103

5.  Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.

Authors:  David E Cohn; Michael W Sill; Joan L Walker; David O'Malley; Christa I Nagel; Teresa L Rutledge; William Bradley; Debra L Richardson; Katherine M Moxley; Carol Aghajanian
Journal:  Gynecol Oncol       Date:  2017-07-27       Impact factor: 5.482

6.  Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy?

Authors:  Jay D Naik; Christopher J Twelves; Peter J Selby; Richard G Vile; John D Chester
Journal:  Clin Cancer Res       Date:  2011-05-16       Impact factor: 12.531

7.  Oncogenic Ras inhibits IRF1 to promote viral oncolysis.

Authors:  Y Komatsu; S L Christian; N Ho; T Pongnopparat; M Licursi; K Hirasawa
Journal:  Oncogene       Date:  2014-10-27       Impact factor: 9.867

8.  Cleavage of the C-Terminal Fragment of Reovirus μ1 Is Required for Optimal Infectivity.

Authors:  Anthony J Snyder; Pranav Danthi
Journal:  J Virol       Date:  2018-02-26       Impact factor: 5.103

9.  Oncolytic reovirus effectively targets breast cancer stem cells.

Authors:  Paola Marcato; Cheryl A Dean; Carman A Giacomantonio; Patrick W K Lee
Journal:  Mol Ther       Date:  2009-03-17       Impact factor: 11.454

10.  REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors.

Authors:  Don G Morris; Xiaolan Feng; Lisa M DiFrancesco; Kevin Fonseca; Peter A Forsyth; Alexander H Paterson; Matt C Coffey; Brad Thompson
Journal:  Invest New Drugs       Date:  2012-08-12       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.